High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population-Reference-Cited by-同舟云学术

High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population

Published:2018-10-29 Issue:2 Volume:25 Page:242-248
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Wagner Dimitrios L.^ORCID,Amini Leila^ORCID,Wendering Desiree J.,Burkhardt Lisa-Marie^ORCID,Akyüz Levent,Reinke Petra,Volk Hans-Dieter^ORCID,Schmueck-Henneresse Michael

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0204-6.pdf

Reference44 articles.

1. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

2. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).

3. Chew, W. L. et al. A multifunctional AAV–CRISPR–Cas9 and its host response. Nat. Methods 13, 868–874 (2016).

4. Chew, W. L. Immunity to CRISPR Cas9 and Cas12a therapeutics. Wiley Interdiscip. Rev. Syst. Biol. Med. 10, e1408 (2018).

5. Lehrman, S. Virus treatment questioned after gene therapy death. Nature 401, 517–518 (1999).

Cited by 301 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered Cas9 variants bypass Keap1-mediated degradation in human cells and enhance epigenome editing efficiency;Nucleic Acids Research;2024-09-04

2. Harnessing the evolving CRISPR/Cas9 for precision oncology;Journal of Translational Medicine;2024-08-08

3. Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads;Advanced Drug Delivery Reviews;2024-08

4. In vivo evaluation of guide-free Cas9-induced safety risks in a pig model;Signal Transduction and Targeted Therapy;2024-07-19

5. Insights into Prime Editing Technology: A Deep Dive into Fundamentals, Potentials, and Challenges;Human Gene Therapy;2024-07-01